Summary of results obtained from the Cox regression models, in which 5-year EFS/OS was treated as the outcome variable and the number of sites was taken as a continuous covariable
| Cohort . | Outcome . | HR . | 95% CI . | P value . |
|---|---|---|---|---|
| Cohort 1 (n = 77) | EFS | 1.48 | (0.86-2.56) | .160 |
| OS | 1.68 | (0.38-7.43) | .493 | |
| Cohort 2 (n = 72) | EFS | 1.38 | (0.73-2.63) | .323 |
| OS | 1.65 | (0.38-7.14) | .501 |
| Cohort . | Outcome . | HR . | 95% CI . | P value . |
|---|---|---|---|---|
| Cohort 1 (n = 77) | EFS | 1.48 | (0.86-2.56) | .160 |
| OS | 1.68 | (0.38-7.43) | .493 | |
| Cohort 2 (n = 72) | EFS | 1.38 | (0.73-2.63) | .323 |
| OS | 1.65 | (0.38-7.14) | .501 |
The P values were obtained based on Wald tests.
Cohort 1: all 77 patients with cHL; cohort 2: 72 patients with cHL, with 5 excluded because of systemic symptoms.